异基因造血干细胞移植患者输血及造血重建影响因素分析OA

Objective To show the characteristics of blood component transfusion and differences in hematopoietic re-constitution time among patients undergoing allogeneic hematopoietic stem cell transplantation(allo-HSCT)retrospectively,with the aim of identifying factors affecting blood transfusion and hematopoietic reconstitution,and providing evidence for optimizing stem cell collection strategies and developing individualized transfusion regimens.Methods A total of 95 pa-tients who received allo-HSCT treatment in our hospital from January 2023 to December 2025 were enrolled.Data including disease classification,HLA matching status,ABO blood group compatibility,and cellular composition of grafts were ana-lyzed,and differences in red blood cell and platelet transfusion requirements,as well as the hematopoietic reconstitution time,were compared among groups.Factors affecting transfusion requirements and hematopoietic reconstitution time were e-valuated.Results Different disease classifications showed no significant effect on red blood cell or platelet transfusion re-quirements.No statistically significant differences were observed in blood component transfusion volumes or hematopoietic reconstitution time between HLA semi-matched and fully matched status,ABO blood group compatibility,and graft platelet count.A statistically significant difference was observed only in granulocyte engraftment time between the graft MNC count group of(6-10)×106/kg and the(2-4)×106/kg group[12.00(11.00,13.00)vs 18.00(17.00,30.00)days,P<0.05].Regarding graft CD34+cell count,the(6-10)×106/kg group had a platelet transfusion volume of 3.00(3.00,4.00)therapeutic units,with granulocyte and platelet engraftment time of 11.00(10.25,13.75)days and 12.00(11.00,14.00)days,respectively;the(>10)×106/kg group had corresponding values of 3.00(2.00,3.25)therapeu-tic units,11.50(10.00,12.00)days,and 12.00(11.00,13.00)days.Compared with the(2-4)×106/kg group[6.00(3.00,8.00)therapeutic units,13.00(12.00,15.00)days,15.00(15.50,22.50)days],all these differ-ences were statistically significant(P<0.05).Patients in the CD34+<4×106/kg group demonstrated delayed granulocyte and platelet engraftment and significantly increased platelet transfusion requirements.Conclusion The CD34+cell dose in the graft is a significant correlate of hematopoietic reconstitution time after allo-HSCT and is significantly associated with platelet transfusion requirements.Blood transfusion is a necessary measure for supportive treatment of allo-HSCT patients.Optimizing stem cell harvesting protocols to achieve the target CD34+cell dose,along with developing individualized transfu-sion strategies based on graft CD34+counts,may facilitate hematopoietic recovery,reduce transfusion burden,and ultimate-ly improve patient outcomes after transplantation.